ASCN: New Leadership Will Drive Stronger North American Opportunity Outlook

Analysts have raised their price target on Ascom Holding by CHF 0.00 to reflect slightly higher expectations for revenue growth and profit margins, partly offset by a modestly higher discount rate and a lower assumed future P/E multiple.

What's in the News

• The Board has appointed David Hale as the new CEO of Ascom Holding, effective February 4, 2026. He brings over 25 years of international medtech and pharma leadership experience (Key Developments).
• The interim CEO role will end when Hale joins, and current interim CEO Michael Reitermann will return to his position as an ordinary member of the Board of Directors (Key Developments).
• Reitermann, a long-standing board member with extensive US and European medtech experience, was previously appointed Delegate of the Board and interim CEO after former CEO Nicolas Vanden Abeele decided to leave Ascom (Key Developments).
• The Board aims to accelerate execution of Ascom’s current strategy and sharpen its focus on growth opportunities in the USA and Canada under the refreshed leadership structure (Key Developments).

Valuation Changes

• Fair value estimate remains unchanged at CHF 6.8 per share, indicating no revision to the intrinsic value assessment.
• The discount rate has increased slightly from 4.76 percent to about 4.98 percent, reflecting a modestly higher perceived risk or required return.
• The revenue growth assumption has risen slightly from about 3.21 percent to roughly 3.47 percent, pointing to marginally stronger top line expectations.
• The net profit margin has increased moderately from about 5.88 percent to roughly 6.38 percent, signaling an improved outlook for profitability.
• The future P/E multiple has been reduced slightly from about 16.1x to around 15.3x, implying a more conservative view on the valuation investors may pay for future earnings.